ASCO Annual Meeting 2024
Experts across clinical, medical affairs, and commercial are working hard every day to de-risk drug development by leveraging experience, insights and capabilities that offer thoughtful, integrated solutions. In pursuing new products to help cancer patients see better outcomes, there are inherent, unique challenges and considerations. Customers leverage our experience, insights and capabilities every day to overcome these challenges and achieve more efficient oncology drug development.
Meet with us at ASCO (booth#14095) to discuss how we can help you balance the excitement of innovation against the operational realities of bringing complex therapies to cancer patients.
Our Attendees
Bhawana Awasthy, MD,DNB | Vice President, MSM & General Manager, India
Wael A Harb, MD | Vice President of Medical Affairs
Patrick Kelly, MD | Vice President of Medical Management
Matt Lehmann | Executive Vice President of Global Commercial Business Development
Daniel Mazzolenis, MD, MBA | Senior Vice President of Medical Management
Patrick Melvin | Vice President, Novel and Emerging Therapies, TA Lead, Hematology/Oncology
Related Content:
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Insights by Indication
Is Your NSCLC Asset Ready to Create Value Post-FDA Approval?: Our experts revisit and refine four value considerations to reflect on the creativity necessary to deliver NSCLC innovative therapies to patients at a rapid pace.
Oncology and the Evolution of Master Clinical Trials | Lessons from the Beat AML Master Trial: Leveraging experiences from managing the Beat AML Master Trial, our experts share the importance of innovative trial design, data analysis and patient-centricity in managing large-scale platform oncology trials.
Podcast | Opportunities and Challenges in Cell and Gene Therapy: Discussion on genetic medicine market access challenges and how to build a case for continued investment in innovative therapies
Pediatric Cancers, Like All Rare Conditions, Will Benefit from A ‘Warp Speed’ Mindset: Understand the public-private backing for childhood cancers, hurdles to innovation, and how to assist families with hard choices.
Our Capabilities
Oncology Expertise at all Levels
End-to-End Expertise in Early-Phase Oncology
Targeted Therapies for Solid-Tumors
Syneos Health Pregnancy Exposure Research Studies: Pregnancy Safety Studies provide invaluable insights, guiding your therapies towards safer, more effective outcomes.
Webinar | How AI is Supercharging Clinical Trials: Opportunities created by AI, both traditional and generative in a clinical trial setting.
Putting Patients First: Principles for End-of-Trial Communications: Best practices for improving consistency and outcomes of patient communication through end of trial participation.
Medical Affairs Case Studies: Our RSLs deliver oncology scientific and operational expertise that accelerate trials and improve outcomes.
